Morphosys said more patients would be recruited for a study testing the German biotech company’s most advanced drug against a common type of blood cancer, following an encouraging interim data readout.
U.S. drugmaker Bristol-Myers Squibb Co. reported higher-than-expected third-quarter 2019 profit, helped by strong sales of the blood thinner Eliquis, even as growth of the company’s blockbuster cancer treatment Opdivo slowed.
FDA Approves Janssen’s Darzalex Combo Regimen for Newly Diagnosed, Transplant-Eligible Patients with MM
The U.S. Food and Drug Administration approved Janssen’s Darzalex (daratumumab) in combination with bortezomib, thalidomide and dexamethasone for newly diagnosed patients with multiple myeloma who are eligible for autologous stem cell transplant.
GlaxoSmithKline said an experimental multiple myeloma treatment showed a meaningful response in patients that have run out of three previous treatment options.
AstraZeneca’s BTK inhibitor Calquence won Breakthrough Therapy Designation from the U.S. FDA as a monotherapy treatment for patients with chronic lymphocytic leukemia (CLL).
The U.S. Food and Drug Administration approved Pfizer Inc.’s Ruxience (rituximab-pvvr) – a biosimilar to Rituxan (rituximab) – for the treatment of adult patients with non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, and granulomatosis with polyangiitis and microscopic polyangiitis.
Copenhagen, Denmark-based Genmab A/S raised $506 million with an initial public offering (IPO), with the company trading on the Nasdaq under the ticker symbol GMAB.
ImmunoGen shares fell after the company announced the slashing of 220 employees as part of an effort to reduce ongoing expenses while recovering from an FDA rejection of an ovarian cancer drug.
The U.S. FDA declined to approve Daiichi Sankyo Co.’s drug quizartinib as a treatment for adults with a type of blood cancer.
Calquence Significantly Prolonged Time Patients Lived without Disease Progression in Relapsed or Refractory Chronic Lymphocytic Leukemia
AstraZeneca announced detailed results from the interim analysis of the Phase III ASCEND trial at the European Hematology Association Annual Congress in Amsterdam, showing Calquence (acalabrutinib) significantly prolonged the time patients lived without disease progression in relapsed or refractory chronic lymphocytic leukemia.